Responses
Clinical and epidemiological research
Extended report
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
Compose a Response to This Article
Other responses
No responses have been published for this article.